<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03299166</url>
  </required_header>
  <id_info>
    <org_study_id>BHV4157-202</org_study_id>
    <nct_id>NCT03299166</nct_id>
  </id_info>
  <brief_title>BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceutical Holding Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biohaven Pharmaceutical Holding Company Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of BHV-4157 versus placebo in subjects
      with Obsessive Compulsive Disorder (OCD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to end of double-blind phase of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed using the frequency of subjects with serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.</measure>
    <time_frame>during the double-blind phase (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in functional disability assessed using the Sheehan Disability Scale (SDS) total score.</measure>
    <time_frame>Change from baseline to the end of the double-blind phase (12 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the improvement on the clinical global impression of severity scale (CGI-S).</measure>
    <time_frame>As measured by the change at the end of the double-blind phase of the study (Week 12).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Y-BOCS obsessions sub-scale score.</measure>
    <time_frame>Change from baseline to the end of the double-blind phase (12 weeks).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>BHV-4157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHV-4157</intervention_name>
    <description>BHV-4157, 140mg capsule QD</description>
    <arm_group_label>BHV-4157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching capsule QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary diagnosis of obsessive-compulsive disorder (OCD) as per Diagnostic and
             Statistical Manual of Mental Disorders, Fifth Edition as confirmed by the MINI at
             Screening; The duration of the subject's illness must be ≥ 1 year;

          2. Subjects must be currently experiencing non-response or inadequate response to their
             current Standard of Care (SOC) medication defined as:

               1. Subjects Y-BOCS total score must be ≥ 19 at Screening and Baseline, reflecting
                  moderate or severe OCD symptoms.

               2. Subjects must currently be on a selective serotonin reuptake inhibitor (SSRI),
                  clomipramine, venlafaxine or desvenlafaxine for an adequate duration and at an
                  adequate dose defined as:

             i. Adequate Duration: At least 8 weeks at screening and 10 weeks of SSRI,
             clomipramine, venlafaxine or desvenlafaxine at Baseline.

             ii. Adequate Dose: Defined by the USPI labeling.

          3. Subjects must be on stable doses of other psychotropic medication (with exclusions)
             for at least 12 weeks prior to screening;

          4. CGI-S score of ≥ 4 at screening and baseline;

          5. Determined by the investigator to be medically stable at baseline/randomization as
             assessed by medical history, physical examination, laboratory test results, and
             electrocardiogram testing. Subjects must be physically able and expected to complete
             the trial as designed;

          6. Minimum of 6 years of education or equivalent and sufficiently fluent in English to
             complete necessary scales and understand consent forms;

          7. Subjects must have adequate hearing, vision, and language skills to perform
             neuropsychiatric testing and interviews as specified in the protocol;

          8. Subjects must be able to understand and agree to comply with the prescribed dosage
             regimens and procedures; report for regularly scheduled office visits; and reliably
             communicate with study personnel about adverse events and concomitant medications;

          9. It is required that all women of child-bearing potential (WOCBP) who are sexually
             active agree to use two methods of contraception for the duration of the study (i.e.
             beginning 30 days prior to baseline and extending to 30 days after the last dose of
             study drug). The two methods should include:

               1. one barrier method (e.g. diaphragm with spermicide, condom with spermicidal gel,
                  intrauterine devices, cervical cap);

               2. and one other method. The other method could include oral contraceptives or
                  another barrier method (Section 5.5);

         10. Women of childbearing potential must have a negative serum pregnancy test at screening
             and a negative urine pregnancy test prior to dosing at Baseline;

         11. It is required that men who are sexually active with WOCBP agree to use two methods of
             contraception for the duration of the study (beginning at first treatment and
             extending to 90 days after the last dose of study drug).

        Exclusion Criteria:

          1. Subjects should be excluded with a history of more than two (2) previous failed
             treatment trials of SSRIs, clomipramine, venlafaxine, or desvenlafaxine (not including
             the current SSRI trial) given for an adequate duration at an adequate dose as defined
             by the following criteria taken from the MGH-TRQ-OCD as:

               1. Treatment failure / non-response: As per the MGH-TRQ-OCD, there has been minimal
                  or no meaningful clinical benefit as perceived by the patient despite an adequate
                  dose and duration of treatment;

               2. Adequate duration: At least 10 weeks of treatment with SSRI, clomipramine,
                  venlafaxine, or desvenlafaxine

               3. Adequate dose: Defined by the USPI labeling.

          2. Subjects should be excluded at screening or baseline if any medical or psychiatric
             condition other than OCD, as specified in the inclusion criteria, could predominantly
             explain or contribute significantly to the subjects' symptoms or that could confound
             assessment of OCD symptoms;

          3. MMSE score of &lt; 24 at Screening;

          4. Current or prior history, per DSM-V criteria, of bipolar I or II disorder,
             schizophrenia or other psychotic disorders, schizoaffective disorder, autism or
             autistic spectrum disorders, borderline personality disorder, antisocial personality
             disorder, body dysmorphic disorder, hoarding disorder (symptoms of hoarding disorder
             as part of the OCD diagnosis are allowed, but a primary diagnosis of hoarding disorder
             is excluded); a current diagnosis of Tourette's disorder is also excluded;

          5. Any eating disorder within the last 12 months;

          6. Primary active major depressive episode or primary active anxiety disorder within the
             past 6 months. Note: Subjects on a stable maintenance dose of a non-tricyclic,
             non-monoamine oxidase inhibitor (MAOI) antidepressant medication with symptoms in
             remission may be eligible if the subject has been treated with a stable dose for at
             least 3 months prior to randomization and no dose changes are expected throughout the
             randomization phase of the study;

          7. Acute suicidality or suicide attempt or self-injurious behavior in the last 12 months;

          8. Score of &gt;0 on the Sheehan Suicidality Tracking Scale for the period of 6 months prior
             to screening, and at baseline;

          9. Brown Assessment of Beliefs (BABS) score &gt;17 at screening and baseline;

         10. History of psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy
             (ECT).

         11. Transcranial Magnetic Stimulation (TMS) is prohibited within three months prior to
             screening and during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Berman, MD</last_name>
    <phone>203-404-0410</phone>
    <email>clinicaltrials@biohavenpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling, PhD</last_name>
      <phone>714-799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Sumner</last_name>
      <phone>858-246-1872</phone>
      <email>jsumner@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CalNeuro Research Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Bystritsky</last_name>
      <phone>310-208-7144</phone>
      <email>abystritksy@pacificmedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy Research San Diego</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woody Woodaman</last_name>
      <phone>619-327-0155</phone>
      <email>woody.synergy@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Cote</last_name>
      <phone>510-444-2877</phone>
      <email>shawnacote@pacifictrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chueh, MD</last_name>
      <phone>714-289-1100</phone>
      <email>dchueh@nrcresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Panella</last_name>
      <phone>858-278-3647</phone>
      <email>bpanella@artemis-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Welchers</last_name>
      <phone>760-266-4144</phone>
      <email>bweichers@artemis-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University, Department of Psychiatry and Behavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Varias</last_name>
      <phone>650-723-8912</phone>
      <email>avarias@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Living / Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Brodeur</last_name>
      <phone>860-545-7502</phone>
      <email>allison.brodeur@hhchealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Billingslea</last_name>
      <phone>203-974-7768</phone>
      <email>eileen.billingslea@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Department of Psychiatry</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Mason</last_name>
      <phone>352-273-8540</phone>
      <email>dmason@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Angel</last_name>
      <phone>904-281-5757</phone>
      <email>sangel@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SIH Research, Inc</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanza Chaudhary</last_name>
      <phone>407-483-5389</phone>
      <email>kanza.chaudhary@sihresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harmony Clinical Research</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Gamon</last_name>
      <phone>305-957-7200</phone>
      <email>rgamon@hcresearchfl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan McMahon</last_name>
      <phone>386-775-7627</phone>
      <email>mmcmahon@mrgcf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Brown</last_name>
      <phone>407-425-5100</phone>
      <email>pbrown@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Goza</last_name>
      <phone>404-537-1281</phone>
      <email>amanda.goza@iresearchatlanta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Department of Psychiatry &amp; Behavioral Neuroscience</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Redden</last_name>
      <phone>773-702-9066</phone>
      <email>sredden@bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR-Baber Research, Inc</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeshawn Ahmed</last_name>
      <phone>312-890-2177</phone>
      <email>Zeshawn@BaberResearchGroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Bauer</last_name>
      <phone>913-381-7180</phone>
      <email>bbauer@pmr-kc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Thome</last_name>
      <phone>316-689-6629</phone>
      <email>amrbudgets@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research, Inc.</name>
      <address>
        <city>Pikesville</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nelson</last_name>
      <phone>410-602-1440</phone>
      <email>jnelson@pharmasiteresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Perriello</last_name>
      <phone>617-855-2911</phone>
      <email>cperriello@mclean.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Porth</last_name>
      <phone>617-726-5527</phone>
      <email>Rporth@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research, Inc.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rocha</last_name>
      <phone>978-655-7155</phone>
      <email>lrocha@activemedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayon Choe</last_name>
      <phone>856-857-9500</phone>
      <phone_ext>19</phone_ext>
      <email>kchoe@cfef.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Middleton</last_name>
      <phone>646-774-8138</phone>
      <email>rachel.middleton@NYSPI.Columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Smith</last_name>
      <phone>718-317-5522</phone>
      <email>smith@rbany.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Jackson</last_name>
      <phone>937-424-1050</phone>
      <email>Cjackson@midwestclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon) Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tawnya Andersen</last_name>
      <phone>503-228-2273</phone>
      <email>Oregon@summitnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suburban Research Associates</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Varney</last_name>
      <phone>610-891-9024</phone>
      <phone_ext>118</phone_ext>
      <email>nvarney@suburbanresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thea Gallager</last_name>
      <phone>215-573-3708</phone>
      <email>theaga@mail.med.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Grandberry</last_name>
      <phone>901-843-1045</phone>
      <email>cgrandberry@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Ashmore</last_name>
      <phone>214-369-2600</phone>
      <email>erina@fstrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Green</last_name>
      <phone>972-283-6286</phone>
      <email>bgreen@incr.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Vogt</last_name>
      <phone>713-798-4729</phone>
      <email>gsvogt@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Alliance of the Blue Ridge, Inc.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angel Morris</last_name>
      <phone>434-984-6777</phone>
      <email>morrisangel@pabrcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Kahn</last_name>
      <phone>425-453-0404</phone>
      <email>akhan@nwcrc.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

